Ezabenlimab

Phase 1Monoclonal antibody

Ezabenlimab is one of 159 monoclonal antibody programs targeting Pancreatic Ductal Adenocarcinoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

158

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic Ductal AdenocarcinomaActive, not recruiting

NeoplasmsActive, not recruiting

Advanced Solid CancerRecruiting

Small Cell Lung Carcinoma (SCLC)Active, not recruiting

Carcinoma, Squamous Cell of Head and NeckActive, not recruiting

Cancer (solid Tumors)Not yet recruiting

GlioblastomaActive, not recruiting

Solid TumorRecruiting

Pancreatic Ductal AdenocarcinomaPhase 1

Active, not recruiting

NeoplasmsPhase 1

Active, not recruiting

Advanced Solid CancerPhase 1

Recruiting

Small Cell Lung Carcinoma (SCLC)Phase 1

Active, not recruiting

Carcinoma, Squamous Cell of Head and NeckPhase 1

Active, not recruiting

Cancer (solid Tumors)Phase 1

Not yet recruiting

GlioblastomaPhase 1

Active, not recruiting

Solid TumorPhase 1

Recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

DATROWAY

Daiichi Sankyo

Preclinical

1 2

Fludara

Sanofi

Preclinical

1 3

Ezabenlimab

Boehringer Ingelheim

Phase 1

2 4

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

2 5

Proleukin

IIovance Biotherapeutics, Inc.

Preclinical

1 6

Navmi

SSummit Therapeutics

Preclinical

1 7

Paxil

SSebela Pharmaceuticals Development LLC

Preclinical

1 8

Tulmimetostat

Novartis

Preclinical

1 9

Carboplatin AUC-5

Merck & Co.

Preclinical

1 10

Soc

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Active, not recruiting

Pancreatic Ductal Adenocarcinoma

NCT05846516

Phase 1Active, not recruiting

Solid Tumor

NCT05327946

Phase 1Active, not recruiting

Small Cell Lung Carcinoma (SCLC)

NCT05879978

Q3 2027

Phase 1Active, not recruiting

Carcinoma, Squamous Cell of Head and Neck

NCT05068102

Q1 2028

Phase 1Active, not recruiting

Neoplasms

NCT04958239

Q1 2029

Phase 1Recruiting

Solid Tumor

NCT05471856

Clinical

Trials by Indication[1]

Cancer (Solid Tumors)2 trials

A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT03964233·119 enrolled

A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)

Not yet recruiting· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT07395258·60 enrolled

Solid Tumor2 trials

An Open-label, Phase I Dose Escalation Followed by Dose Expansion Trial in Patients With Advanced Solid Tumours to Investigate Safety, Pharmacokinetics, and Efficacy and to Select the Dose for Further Development of BI 770371 in Combination With Ezabenlimab

Active, not recruiting· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT05327946·42 enrolled

Phase Ia, First in Human Open Label Dose Escalation Trial Evaluating Intravenous BI 1703880 in Combination With Intravenous Ezabenlimab for Treatment of Advanced Solid Tumours

Recruiting· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT05471856·66 enrolled

Advanced Cancer1 trial

This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT03156114·172 enrolled

Soft Tissue Sarcoma1 trial

Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma

Withdrawn· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT06370871

Safety and Efficacy1 trial

Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT03697304·211 enrolled

12 more indications

Cancer1 trial

This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT03433898·146 enrolled

Patients With Advanced Solid Tumors1 trial

A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT04752215·67 enrolled

Glioblastoma1 trial

Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma

Active, not recruiting·JJohann Wolfgang Goethe University Hospital·Phase 1·NCT03383978·42 enrolled

Non-Small Cell Lung Cancer1 trial

A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT03468426·252 enrolled

Colorectal Cancer1 trial

A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery

Terminated· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT05446129·2 enrolled

Head and Neck Squamous Cell Carcinoma (HNSCC)1 trial

An Open Label Trial of BI 765063 in Combination With BI 754091 (Ezabenlimab) Alone or With BI 836880, Chemotherapy, or Cetuximab, in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) or Hepatocellular Carcinoma (HCC)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT05249426·48 enrolled

Gastrointestinal Cancer1 trial

Phase I, Non-randomised, Open-label, Multi-centre Dose Escalation and Expansion Trial of BI 765049 and BI 765049 + Ezabenlimab Administered by Repeated Intravenous Infusion in Asian Patients With Malignant Solid Tumours Expressing B7-H6

Terminated· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT06091930·21 enrolled

Neoplasms1 trial

An Open Label, Phase I Dose-finding and Expansion Study of BI 765179 as Monotherapy and in Combination With Ezabenlimab (BI 754091) in Patients With Advanced Solid Cancers, and BI 765179 in Combination With Pembrolizumab in First-line PD-L1-positive Metastatic or Incurable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)

Active, not recruiting· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT04958239·151 enrolled

Pancreatic Ductal Adenocarcinoma1 trial

A Phase 1b Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Heterologous Prime Boost Vaccination (ATP150/ATP152/ATP162, VSV-GP154) and Ezabenlimab (BI 754091) in Patients With Pancreatic Ductal Adenocarcinoma.

Active, not recruiting· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT05846516·59 enrolled

Carcinoma, Squamous Cell of Head and Neck1 trial

An Open Label Phase I PET Imaging Study to Investigate the Bio-distribution and Tumor Uptake of [89Zr]Zr-BI 765063 and [89Zr]Zr-BI 770371 in Patients With Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer or Melanoma Who Are Treated With Ezabenlimab

Active, not recruiting· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT05068102·14 enrolled

Small Cell Lung Carcinoma (SCLC)1 trial

A Phase I, Non-randomized, Open-label, Multi-center Dose Escalation Trial of Obrixtamig (BI 764532) Combined With Ezabenlimab in Patients With Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3

Active, not recruiting· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT05879978·45 enrolled

Advanced Solid Cancer1 trial

A First-in-human Phase I, Open-label, Multicentre, Dose Escalation Trial of BI 3819026 in Combination With Ezabenlimab in Patients With Unresectable Advanced or Metastatic Solid Cancers to Determine the Maximum Tolerated Dose (MTD) and Recommended Dose for Expansion (RDE)

Recruiting· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT07607678·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 19 trial records for Ezabenlimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ezabenlimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ezabenlimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 1[1]
Company: Boehringer Ingelheim

Ezabenlimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2027

Q1 2028

Q1 2029

Trials by Indication[1]

Cancer (Solid Tumors)2 trials

Solid Tumor2 trials

Advanced Cancer1 trial

Soft Tissue Sarcoma1 trial

Safety and Efficacy1 trial

Cancer1 trial

Patients With Advanced Solid Tumors1 trial

Glioblastoma1 trial

Non-Small Cell Lung Cancer1 trial

Colorectal Cancer1 trial

Head and Neck Squamous Cell Carcinoma (HNSCC)1 trial

Gastrointestinal Cancer1 trial

Neoplasms1 trial

Pancreatic Ductal Adenocarcinoma1 trial

Carcinoma, Squamous Cell of Head and Neck1 trial

Small Cell Lung Carcinoma (SCLC)1 trial

Advanced Solid Cancer1 trial

References

Drug Info

Quick Facts

Related News